
#JPM22: Catalent CEO John Chiminski with John Carroll — Our predictions for the biopharma industry in 2022
During our JPM22 week of events, I had a chance to sit down with Catalent CEO John Chiminski for our annual forecast for the year ahead. It’s always a lot of fun, and Chiminski had a chance to talk about the big transition ahead for his company, CDMOs, and what looks like a very eventful 12 months for biopharma. — John Carroll
John Carroll:
Okay! Well. Hey, everybody. This is John Carroll, I’m the editor of Endpoints News. And I am very happy to introduce John Chiminski back again, CEO of Catalent. And John is joining me once again to be talking about what’s going on next year, what’s happening. We’ve done this before. Generally, it’s always good to have you be here, John. But one thing that we can say that’s absolutely certain that’s going to happen in 2022 is there’s going to be a transition at Catalent. And I wanted to talk a little bit about that.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters